Integrin alpha 4/CD49d Antibody (Natalizumab) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-75916F
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Block/Neutralize, Flow Cytometry
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Monoclonal Human IgG4 kappa Clone # Natalizumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
The RAMOS cell line, a non-EBV releasing cell line, injected into mice.
Specificity
This antibody binds to the alpha 4 subunit of (alpha)4(beta)1 (also known as very late antigen 4 (VLA-4) or CD49d-CD29) and (alpha)4(beta)7 integrin
Clonality
Monoclonal
Host
Human
Isotype
IgG4 kappa
Applications for Integrin alpha 4/CD49d Antibody (Natalizumab) [FITC]
Application
Recommended Usage
Block/Neutralize
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Integrin alpha 4/CD49d
Alternate Names
CD49d, ITGA4, VLA-4
Gene Symbol
ITGA4
Additional Integrin alpha 4/CD49d Products
Product Documents for Integrin alpha 4/CD49d Antibody (Natalizumab) [FITC]
Product Specific Notices for Integrin alpha 4/CD49d Antibody (Natalizumab) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...